Volume 5, Issue 1, January 2017, Page: 10-14
Profile of mRNA Expression of Ki-67 in Breast Cancer Patients Pre- and Post- Chemotherapy
Prihantono Prihantono, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Daniel Sampepajung, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Andi Asadul Islam, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Mochammad Hatta, Molecular Biology and Immunology Laboratory, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Warsinggih Rahardjo, Department of Surgery, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Christian Binekada, Department of Surgery, Faculty of Medicine, Haluoleo University, Kendari, Indonesia
Eddy Herman Tanggo, Department of Surgery, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
Received: Dec. 7, 2016;       Accepted: Dec. 20, 2016;       Published: Jan. 19, 2017
DOI: 10.11648/j.ajcem.20170501.13      View  2734      Downloads  73
Abstract
Background: Proliferation is a distinct hallmarks of cancer. Ki-67 designated as a marker of proliferation in solid tumors. The proliferative activity of tumor demonstrated by expression of Ki-67 in breast cancer has been associated with a poor prognosis. Changes in the relative proportions of Ki-67 can be observed during chemotherapy and may correlated with clinical response in breast cancer. Purpose: Evaluate changes in mRNA expression of proliferation marker Ki-67 in breast cancer patients pre- and post-chemotherapy in relation with clinical response to chemotherapy. Method: This is a longitudinal study, 30 subjects breast cancer tissue samples pre- and post-chemotherapy using cyclophosphamide, adriamycin, 5FU regiment. We using qRT-PCR techniques to detect mRNA expression of Ki-67. Chemotherapy response is calculated using RECIST criteria. Results: Mean value of Ki-67 mRNA expression on breast cancer patients pre-chemotheraphy was 11.837±0.360. Mean value of Ki-67 mRNA expression on breast cancer patients post-chemotheraphy was 11.241±1.971. There was no significant correlation between expression of Ki-67 mRNA prechemotherapy with clinical response to chemotherapy, p = 0.862 (p ≥0.05). There is a positive correlation between velocity of Ki-67 mRNA expression with clinical response with value of r = 0.378, this correlation was significant with p = 0.020 (p<0.05). Conclusion: Chemotherapy cause decrease in mRNA expression of Ki-67. There is insignificant correlation between expression of mRNA Ki-67 baseline with chemotherapy response. Velocity of Ki-67 mRNA expression has significant correlation with clinical response to chemotherapy.
Keywords
Breast Cancer, Chemotherapy, mRNA, Ki-67, QRT-PCR
To cite this article
Prihantono Prihantono, Daniel Sampepajung, Andi Asadul Islam, Mochammad Hatta, Warsinggih Rahardjo, Christian Binekada, Eddy Herman Tanggo, Profile of mRNA Expression of Ki-67 in Breast Cancer Patients Pre- and Post- Chemotherapy, American Journal of Clinical and Experimental Medicine. Vol. 5, No. 1, 2017, pp. 10-14. doi: 10.11648/j.ajcem.20170501.13
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144 (5): 646-74.
[2]
Scholzen T, Gerdes J. The Ki‐67 protein: from the known and the unknown. Journal of cellular physiology. 2000;182 (3): 311-22.
[3]
Van Diest P, Van Der Wall E, Baak J. Prognostic value of proliferation in invasive breast cancer: a review. Journal of clinical pathology. 2004;57 (7): 675-81.
[4]
Jones RL, Salter J, A’Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast cancer research and treatment. 2009;116 (1): 53-68.
[5]
Goldhirsch A, Winer EP, Coates A, Gelber R, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology. 2013; 24 (9): 2206-23.
[6]
Marme F, Schneeweiss A, Aigner J, Eidt S, Altevogt P, Sinn P, et al. Abstract P3-06-08: Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Research. 2012;72(24 Supplement): P3-06-8-P3--8.
[7]
Williams SL, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol. 2009; 2 (5): 476-80.
[8]
Boom R, Sol C, Salimans M, Jansen C, Wertheim-van Dillen P, Van der Noordaa J. Rapid and simple method for purification of nucleic acids. Journal of clinical microbiology. 1990; 28 (3): 495-503.
[9]
Mitas M, Mikhitarian K, Walters C, Baron PL, Elliott BM, Brothers TE, et al. Quantitative real‐time RT‐PCR detection of breast cancer micrometastasis using a multigene marker panel. International journal of cancer. 2001; 93 (2): 162-71.
[10]
Potemski P, Pluciennik E, Bednarek AK, Kusinska R, Kubiak R, Jesionek-Kupnicka D, et al. Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay. Pathology-Research and Practice. 2006; 202 (7): 491-5.
[11]
Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. Journal of breast cancer. 2014; 17 (4): 376-85.
[12]
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research. 2005;11 (16): 5678-85.
[13]
Engstrøm MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast cancer research and treatment. 2013; 140 (3): 463-73.
[14]
Lønning PE. Poor-prognosis estrogen receptor-positive disease: present and future clinical solutions. Therapeutic advances in medical oncology. 2012: 1758834012439338.
[15]
Colleoni M, Montagna E. Neoadjuvant therapy for ER-positive breast cancers. Annals of Oncology. 2012; 23(suppl 10): x243-x8.
[16]
Zhang J, Liu Y. HER2 over-expression and response to different chemotherapy regimens in breast cancer. Journal of Zhejiang University Science B. 2008; 9 (1): 5-9.
[17]
Hamy-Petit A-S, Belin L, Bonsang-Kitzis H, Paquet C, Pierga J-Y, Lerebours F, et al. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort. British journal of cancer. 2016; 114 (1): 44-52.
[18]
Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute. 2011.
[19]
Luporsi E, André F, Spyratos F, Martin P-M, Jacquemier J, Penault-Llorca F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast cancer research and treatment. 2012; 132 (3): 895-915.
[20]
Denkert C, Sinn BV, Issa Y, Müller BM, Maisch A, Untch M, et al. Prediction of response to neoadjuvant chemotherapy: new biomarker approaches and concepts. Breast Care. 2011;6 (4): 265-72.
[21]
Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart M. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Annals of oncology. 2005; 16 (11): 1723-39.
[22]
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. The lancet oncology. 2010; 11 (2): 174-83.
[23]
Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. Journal of the National Cancer Institute. 2008; 100 (3): 207-12.
[24]
Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptor–positive breast cancer. Journal of Clinical Oncology. 2009;27 (17): 2809-15.
[25]
Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen P-L, Auvinen P, et al. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast cancer research and treatment. 2016: 1-10.
Browse journals by subject